ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2502

Contributions Of Skin and Joint Manifestations To The Parent-Of-Origin Effect In Psoriatic Disease

Remy Pollock1, Arane Thavaneswaran2, Vinod Chandran3, Art Petronis4, Al Amin P. Rahman5 and Dafna D. Gladman3, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4The Krembil Family Epigenetics Laboratory, Centre for Addiction and Mental Health, Toronto, ON, Canada, 5Medicine, Memorial University, St Johns, NE, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Epigenetics and psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis: Pathogenesis, Etiology, Animal Models II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Excessive paternal transmission has been previously documented in psoriatic disease. Our objective is to delineate the differential contributions of skin and joint manifestations to this ‘parent-of-origin’ effect, and determine whether the effect is differentially associated with psoriasis or PsA.

Methods:

Parental history of PsA and/or psoriasis without arthritis was ascertained by questionnaire or during clinical assessment of PsA and psoriasis patients from two large cohorts. Data was combined with previously-published data. Proportions of maternal and paternal transmissions were compared using a normal approximation to the binomial distribution. Parental and patient phenotypes were resolved where possible into psoriasis alone or PsA and compared by chi-square test and logistic regression. Patients with paternally and maternally-transmitted disease were compared with respect to demographic and clinical characteristics as well as carriage of risk alleles at HLA-B, -C, –DR, –DQ, and MICA, using Student’s t-test or chi-square test.

Results:

We found a preponderance of patients with affected fathers compared to affected mothers in the combined analysis (397 [56%] versus 313 [44%], p=0.002). There was a greater excess of paternal transmissions in patients with a parental history of psoriasis (223 [58%] versus 162 [42%], p=0.002) compared to patients with a parental history of PsA (75 [54%] versus 65 [46%], p=0.45), but no difference in frequencies between these patients (p=0.37). Although the parent-of-origin effect also appeared to be stronger in PsA than in psoriasis patients, paternal history of psoriasis could not predict PsA. PsA patients with paternally-transmitted psoriasis had fewer damaged joints than patients with maternally-transmitted psoriasis (mean damaged joint count 6.3 compared to 12.9, p=0.04), and PsA patients with paternally-transmitted PsA had an earlier age of PsA diagnosis than patients with maternally-transmitted PsA (mean age 32.8 compared to 37.5 years, p=0.05). In one particular cohort, PsA patients with paternally-transmitted psoriasis had lower carriage rates of HLA-B*38 (p=0.006), HLA-C*06 (p=0.03), and MICA-129Met (p=0.01).

Conclusion:

We have provided additional evidence of a parent-of-origin effect in psoriatic disease, which may be driven by paternal transmission of psoriasis without arthritis and may be characterized by an earlier-onset yet milder disease that is not associated with several known risk alleles in the MHC.


Disclosure:

R. Pollock,
None;

A. Thavaneswaran,
None;

V. Chandran,
None;

A. Petronis,
None;

A. A. P. Rahman,
None;

D. D. Gladman,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/contributions-of-skin-and-joint-manifestations-to-the-parent-of-origin-effect-in-psoriatic-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology